Condition: Locally Advanced Cervical Adenocarcinoma · Locally Advanced Cervical Adenosquamous Carcinoma · Locally Advanced Cervical Squamous Cell Carcinoma · Sponsor: National Cancer Institute (NCI)
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding induction chemotherapy to the usual treatment of chemotherapy and radiation followed by maintenance may be more effective in treating patients with high risk, locally advanced cervical cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Not Yet Recruiting |
| Highlands Oncology Group - Fayetteville | Fayetteville, Arkansas, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| Highlands Oncology Group - Rogers | Rogers, Arkansas, United States | Recruiting |
| Highlands Oncology Group | Springdale, Arkansas, United States | Recruiting |
| Kaiser Permanente-Bellflower | Bellflower, California, United States | Recruiting |
| City of Hope Corona | Corona, California, United States | Recruiting |
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| Kaiser Permanente South Bay | Harbor City, California, United States | Recruiting |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine, California, United States | Recruiting |
| City of Hope at Irvine Lennar | Irvine, California, United States | Recruiting |
| Kaiser Permanente-Irvine | Irvine, California, United States | Recruiting |
+ 289 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07061977